Key statistics
On Friday, Gyre Therapeutics Inc (L9S:FRA) closed at 6.30, 9.57% above its 52-week low of 5.75, set on Aug 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.30 |
|---|---|
| High | 6.30 |
| Low | 6.30 |
| Bid | 6.60 |
| Offer | 6.70 |
| Previous close | 6.55 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 90.89m |
| Free float | 11.72m |
| P/E (TTM) | 116.34 |
| Market cap | 682.59m USD |
| EPS (TTM) | 0.0646 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Announcements
- Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
- Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
- Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
- Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
- Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
- Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
- Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
- Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
More ▼
